Betaine
Approved medicineAlso known as Abromine, Acidol, Betaína anhidra, Cystadane+17 more
Abromine, Acidol, Betaína anhidra, Cystadane, Glycine betaine, Glycinebetaine, Glykokollbetain, Lycine, Oxyneurine, TMG, Trimethylglycine, Trimethylglycocoll, 2-(Trimethylammonio)Acetate, 2-N,N,N-trimethylammonio acetate, 2-trimethylammonioacetate, Betaine Anhydrous, Betaine Hydrochloride, N,N,N-Trimethylglycine, N,N,N-trimethylammonioacetate, Trimethylaminoacetate, Trimethylammonioacetate.
Recent clinical, regulatory, research and industry developments relating to this drug.
The Effect of Betaine in Refractory Syringomyelia(RS)
Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation
Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes.
Betaine METABOLISM OF PATIENTS With Homocystinuria
A Pilot Study of Choline and Betaine Supplementation in Arsenic-exposed Individuals in Bangladesh
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10 methylene tetrahydrofolate… Show full indicationShow less
Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10 methylene tetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism (cbl).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- The Journal of clinical endocrinology and metabolism1
- Basu R1
- Beckman JA1
- Cloutier E1
- Dreyfuss JM1
- Fowler KM1
- Gerszten RE1
- Goldfine AB1
- Grizales AM1
- Beth Israel Deaconess Medical Center1
- Brigham and Women's Hospital1
- Harvard Medical School1
- Joslin Diabetes Center1
- University of Virginia School of Medicine1
- Vanderbilt University Medical Center1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.